300 results on '"Steg P.G."'
Search Results
2. Standard modifiable risk factors and mortality in patients with ST-segment elevation myocardial infarction: Findings from the FRENCHIE cohort
3. Burden of dementia, chronic kidney disease and cardiovascular diseases attributable to systolic hypertension in France
4. Incidence and predictors of in-hospital complications after myocardial infraction in contemporary clinical practice: Findings from the FRENCHIE myocardial infarction cohort
5. SA1 In Silico Clinical Trials Using Mechanistic Knowledge-Based Model, an Innovative Approach to Accelerate Data Generation and Support Health Technology Assessment
6. Sotagliflozin Significantly Reduces CV Death and Heart Failure-related Outcomes in Patients with Type 2 Diabetes, Chronic Kidney Disease, and History of Heart Failure
7. Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES
8. Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes
9. Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings
10. POTENTIAL IMPACT OF THE 2017 ACC/AHA HIGH BLOOD PRESSURE GUIDELINE IN NORMOTENSIVE PATIENTS WITH STABLE CORONARY ARTERY DISEASE: INSIGHTS FROM THE CLARIFY REGISTRY
11. Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab
12. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial
13. Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome : results from the PLATelet inhibition and patients Outcomes (PLATO) trial
14. Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial
15. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
16. Two-year Vascular Hospitalisation Rates and Associated Costs in Patients at Risk of Atherothrombosis in France and Germany: Highest Burden for Peripheral Arterial Disease
17. Alirocumab after acute coronary syndrome in patients with a history of heart failure
18. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL
19. Predicting 10-year risk of recurrent cardiovascular events andcardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH
20. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention : a prespecified sub-analysis of the GLOBAL LEADERS trial
21. Gut microbiota‐dependent trimethylamine N‐oxide and cardiovascular outcomes in patients with prior myocardial infarction: A nested case control study from the PEGASUS‐TIMI 54 trial
22. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial
23. REPLY: alirocumab in polyvascular atherosclerotic disease
24. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events after Percutaneous Coronary Intervention: The PARIS Registry
25. Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial
26. Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS
27. Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial
28. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial
29. Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial
30. Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial
31. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial
32. Interleukin‐18 in patients with acute coronary syndromes
33. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation:The RE-DUAL PCI Trial Subanalysis
34. Reduced gastric injury with a novel, liquid lipid-aspirin formulation: results from a pooled, patient level analysis of two randomized endoscopy studies In healthy volunteers
35. REDUCE-IT: outcomes by baseline statin type
36. Ticagrelor monotherapy beyond 1 month versus standard dual antiplatelet therapy after drug-eluting coronary stenting: a pre-specified per-protocol analysis of the GLOBAL LEADERS trial
37. Low-density lipoprotein cholesterol <50 mg/dL is an appropriate target after acute coronary syndrome: propensity score-matched analysis of the ODYSSEY OUTCOMES trial
38. Effect of alirocumab on incidence of atrial fibrillation after acute coronary syndromes: insights from ODYSSEY OUTCOMES
39. REDUCE-IT: accumulation of data across prespecified interim analyses to final results
40. CCS patients with polyvascular disease are a high risk but heterogenous subset of patients: insights from the CLARIFY registry
41. REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups
42. Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trial
43. Sleep disordered breathing: prevalence and association with cardiovascular disease in the French general population
44. Prognosis in patients with prior myocardial infarction and PEGASUS-TIMI 54 criteria in the CLARIFY registry
45. Naxos study: risk of bleeding with oral anticoagulants in non-valvular atrial fibrillation patients in France
46. A tale of two countries: costs and financial incentives for provisional stenting during percutaneous coronary intervention in France and the United States
47. Comparaison de la sécurité et de l’efficacité en vraie vie des anticoagulants chez les patients présentant une fibrillation auriculaire non valvulaire : l’étude NAXOS
48. Use of risk score to identify lower and higher risk subsets among COMPASS-Eligible patients with stable CAD. Insights from the CLARIFY Registry
49. NAXOS: Healthcare resource use among patients with non-valvular atrial fibrillation newly treated with apixaban in France, and comparison with other oral anticoagulants
50. Frequency, management and outcomes of patients with stable coronary artery disease eligible for COMPASS. An analysis of the CLARIFY Registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.